|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Articles in PresS, published online ahead of print August 22, 2002
Am J Physiol Heart Circ Physiol, 10.1152/ajpheart.00448.2002
Submitted on May 28, 2002
Accepted on August 15, 2002
1 Biochemistry, University of Iowa, Iowa City, IA, USA
2 Internal Medicine, University of Iowa, Iowa City, IA, USA
3 Entomology, University of California, Davis, CA, USA
4 Biochemistry, University of Iowa, Iowa City, IA, USA; Internal Medicine, University of Iowa, Iowa City, IA, USA
* To whom correspondence should be addressed. E-mail: xiang-fang{at}uiowa.edu.
Cytochrome P-450 epoxygenase-derived epoxyeicosatrienoic acids (EETs) play an important role in the regulation of vascular reactivity and function. Conversion to the corresponding dihydroxyeicosatrienoic acids (DHETs) by soluble epoxide hydrolases is thought to be the major pathway of EET metabolism in mammalian vascular cells. However, when human coronary endothelial cells (HCEC) were incubated with [3H]14,15-EET, chain-shortened epoxy fatty acids, rather than DHET, were the most abundant metabolites. After 4 h of incubation, 23% of the total radioactivity remaining in the medium was converted to 10,11-epoxy-hexadecadienoic acid (16:2), a product formed from 14,15-EET by two cycles of ß-oxidation, while only 15% was present as 14,15-DHET. Although abundantly present in the medium, 10,11-epoxy-16:2 was not detected in cell lipids. Exogenously-applied [3H]10,11-epoxy-16:2 was neither metabolized nor retained in the cells, suggesting that 10,11-epoxy-16:2 is a major product of 14,15-EET metabolism in HCEC. 10,11-Epoxy-16:2 produced potent dilation in coronary microvessels. 10,11-Epoxy-16:2 also potently inhibited tumor necrosis factor a-induced production of interleukin-8, a pro-inflammatory cytokine, by HCEC. These findings implicate ß-oxidation as a major pathway of 14,15-EET metabolism in HCEC and provide the first evidence that EET-derived chain-shortened epoxy fatty acids are biologically active.
This article has been cited by other articles:
![]() |
E. Barbosa-Sicard, T. Fromel, B. Keseru, R. P. Brandes, C. Morisseau, B. D. Hammock, T. Braun, M. Kruger, and I. Fleming Inhibition of the Soluble Epoxide Hydrolase by Tyrosine Nitration J. Biol. Chem., October 9, 2009; 284(41): 28156 - 28163. [Abstract] [Full Text] [PDF] |
||||
![]() |
L.-N. Zhang, J. Vincelette, Y. Cheng, U. Mehra, D. Chen, S.-K. Anandan, R. Gless, H. K. Webb, and Y.-X. Wang Inhibition of Soluble Epoxide Hydrolase Attenuated Atherosclerosis, Abdominal Aortic Aneurysm Formation, and Dyslipidemia Arterioscler Thromb Vasc Biol, September 1, 2009; 29(9): 1265 - 1270. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. A. Spector Arachidonic acid cytochrome P450 epoxygenase pathway J. Lipid Res., April 1, 2009; 50(Supplement): S52 - S56. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. M. Nusing, H. Schweer, I. Fleming, D. C. Zeldin, and M. Wegmann Epoxyeicosatrienoic acids affect electrolyte transport in renal tubular epithelial cells: dependence on cyclooxygenase and cell polarity Am J Physiol Renal Physiol, July 1, 2007; 293(1): F288 - F298. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. A. Spector and A. W. Norris Action of epoxyeicosatrienoic acids on cellular function Am J Physiol Cell Physiol, March 1, 2007; 292(3): C996 - C1012. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Fleming and R. Busse Endothelium-Derived Epoxyeicosatrienoic Acids and Vascular Function Hypertension, April 1, 2006; 47(4): 629 - 633. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Fang, N. L. Weintraub, R. B. McCaw, S. Hu, S. D. Harmon, J. B. Rice, B. D. Hammock, and A. A. Spector Effect of soluble epoxide hydrolase inhibition on epoxyeicosatrienoic acid metabolism in human blood vessels Am J Physiol Heart Circ Physiol, December 1, 2004; 287(6): H2412 - H2420. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Le Quere, E. Plee-Gautier, P. Potin, S. Madec, and J.-P. Salaun Human CYP4F3s are the main catalysts in the oxidation of fatty acid epoxides J. Lipid Res., August 1, 2004; 45(8): 1446 - 1458. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Yu, B. B. Davis, C. Morisseau, B. D. Hammock, J. L. Olson, D. L. Kroetz, and R. H. Weiss Vascular localization of soluble epoxide hydrolase in the human kidney Am J Physiol Renal Physiol, April 1, 2004; 286(4): F720 - F726. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Fornage, E. Boerwinkle, P. A. Doris, D. Jacobs, K. Liu, and N. D. Wong Polymorphism of the Soluble Epoxide Hydrolase Is Associated With Coronary Artery Calcification in African-American Subjects: The Coronary Artery Risk Development In Young Adults (CARDIA) Study Circulation, January 27, 2004; 109(3): 335 - 339. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Visit Other APS Journals Online |